PFE“>
When high yield signals high risk
A 7% yield is a red flag in a market full of green. Pfizer trades at 8.1 times forward earnings-a number that screams “caution.” Earnings are projected to decline 3% annually through 2029. Peers like Johnson & Johnson (2.9%) and Merck (3.9%) offer lower yields but stronger balance sheets. AbbVie’s 3.1% isn’t bad either. These companies trade stability for greed. Pfizer’s dividend is a gamble that management can outwit patent cliffs and pipeline failures. It’s a bet with no guaranteed payout.
The dividend is safe through 2026, perhaps with token raises. But long-term? The board will face choices. A cut isn’t imminent, but growth is a fantasy. Buying Pfizer for its dividend is betting against entropy itself. The 7% yield is a warning label, not a promise. So it goes.
The payout will survive the next few years, maybe with small increases. But the long-term outlook is a question mark. Pfizer’s 7% dividend is less a gift than a dare. Investors are invited to dance with the devil-on a sinking ship. 🚩
Read More
- The Most Anticipated Anime of 2026
- Crypto’s Broken Heart: Why ADA Falls While Midnight Rises 🚀
- ‘Zootopia 2’ Smashes Box Office Records and Tops a Milestone Once Held by Titanic
- Actors With Zero Major Scandals Over 25+ Years
- When Markets Dance, Do You Waltz or Flee?
- Child Stars Who’ve Completely Vanished from the Public Eye
- SOXL vs. QLD: A High-Stakes Tech ETF Duel
- Aave DAO’s Big Fail: 14% Drop & Brand Control Backfire 🚀💥
- BitMine Bets Big on Ethereum: A $451 Million Staking Saga! 💰😄
- Crypto Chaos: Hacks, Heists & Headlines! 😱
2025-09-01 13:20